
==== Front
BMC Infect Dis
BMC Infect Dis
BMC Infectious Diseases
1471-2334
BioMed Central London

9901
10.1186/s12879-024-09901-0
Research
Diagnostic value of the Xpert MTB/RIF assay combined with endobronchial ultrasonography with a guide sheath for peripheral nodular pulmonary tuberculosis
Zhou Lihong 1
Yong Yan 1
Ran Xiaoqin 1
Li Hao 2
Hu Qin qinhu19832023@163.com

1
1 Department of Tuberculosis Diagnosis and Treatment Center of Zhejiang Chinese and Western Medicine Integrated Hospital, No. 208 Huancheng East Road, Gongshu District, Hangzhou, Zhejiang China
2 Department of Tuberculosis Laboratory of Zhejiang Chinese and Western Medicine Integrated Hospital, No. 208 Huancheng East Road, Gongshu District, Hangzhou, Zhejiang China
20 9 2024
20 9 2024
2024
24 101715 3 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

The diagnosis of peripheral isolated nodular lesions that are suspected as pulmonary tuberculosis (PTB) is challenging, which are not easily accessible via conventional bronchoscopy. This study evaluated the combined use of Xpert MTB/RIF assay and endobronchial ultrasonography with a guide sheath (EBUS-GS) for detecting MTB infection in peripheral lung bands, for early detection of PTB.

Methods

The clinical data of 232 patients with suspected peripheral nodular PTB who underwent EBUS-GS between June 2020 and October 2023 were retrospectively reviewed. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) of acid-fast bacilli smear, culture, Xpert MTB/RIF assay, and pathological examination were calculated. To assess diagnostic accuracy, the results of the four methods were directly compared with the final clinical diagnosis.

Results

In total, 146 and 86 patients were clinically diagnosed with peripheral nodular PTB and non-PTB, respectively. The sensitivity, specificity, PPV, NPV, and AUC values of combined Xpert MTB/RIF assay and EBUS-GS were 47.26%, 100.0%, 100.0%, 52.76%, and 0.74; those of acid-fast bacilli smear were 8.22%, 97.67%, 85.71%, 38.53%, and 0.53; those of culture were 31.51%, 100.0%, 100.0%, 46.24%, and 0.66; and those of pathological examination were 23.97%, 97.67%, 94.59%, 43.08%, and 0.61, respectively.

Conclusion

The diagnostic accuracy of the combined Xpert MTB/RIF assay and EBUS-GS was significantly better than that of other conventional tests. Hence, this novel technique can be routinely applied for diagnosing and managing peripheral nodular PTB.

Keywords

Peripheral nodular pulmonary tuberculosis
Xpert MTB/RIF
Endobronchial ultrasound with guide sheath
Mycobacterium tuberculosis infection
Pulmonary tuberculosis
http://dx.doi.org/10.13039/501100014996 Health Commission of Zhejiang Province 2022KY984 HangZhou Municipal Health CommissionA20200673 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Tuberculosis (TB), an infectious disease of the respiratory system caused by Mycobacterium tuberculosis (MTB), is a chronic disease that significantly affects human health [1]. An epidemiological survey by the World Health Organization revealed that 10.6 million new TB cases were recorded in 2021 [2]. According to the site of MTB infection, it is classified as pulmonary TB (PTB) and extrapulmonary TB (EPTB). PTB accounts for approximately 80% of all TB cases [3, 4]. As the respiratory tract is connected to the outside world, patients with PTB, particularly those who are not diagnosed and managed timely, are considered the main source of TB infection. Strict screening and standardized treatment are required for control the TB epidemic more effectively [5]. As high-resolution computed tomography (CT) of the chest is frequently used during health checkups, lung abnormalities can be initially detected, and the lesion type can be further classified. If a diagnosis of TB is made, anti-TB treatment is administered as early as possible. If a malignant tumor is suspected, early surgery is required. Currently, for lesions located in the inner or middle lung bands, conventional bronchoscopy can be employed to reach the lesion site. Routine lavage or biopsy combined with macrogene sequencing and histopathological examination can facilitate a relatively easy diagnosis [6, 7]. However, for peripheral lung lesions (i.e., those located in the branches below the bronchial tubes in the lung segments), the lesion site cannot be reached via conventional bronchoscopy. Moreover, the positivity rate of conventional lavage is low. Thus, the early diagnostic rate remains unsatisfactory [8].

Ultrasound bronchoscopy-guided transbronchial lung biopsy, a novel diagnostic technique, can effectively reach the grade 8–9 bronchus, probe peripheral lesions of the airways, and access surrounding blood vessels [9, 10]. It has superior diagnostic performance, is associated with a lower rate of complications, and is extensively used in the diagnosis of peripheral lung lesions, particularly in oncology [11, 12]. However, the application of this technique in the field of PTB remains limited. If this technique is combined with a guide sheath (GS), the GS can be locally fixed in the lumen, thereby allowing multiple samplings of the lesion and further reducing the risk of bleeding due to physical compression of the GS during surgery.

PTB with isolated nodular lesions is a special type of TB that commonly lacks the characteristic clinical manifestations of TB and is easily confused with other lung diseases such as peripheral lung cancer, lung sarcoma, benign tumors of the lungs, and granulomatous lesions [13, 14]. Diagnosing nodular PTB at an early stage is challenging, particularly if the lesion is located in the peripheral lung bands. In such cases, conventional bronchoscopy fails to adequately approach the lesion. Additionally, CT-guided percutaneous lung aspiration biopsy, which is used to collect samples, is associated with an increased risk of surgical complications such as pneumothorax and bleeding. Hence, the diagnostic accuracy is reduced [15]. Recent research has shown that endobronchial ultrasonography (EBUS) with a GS (EBUS-GS) can be used to reach the bronchial lumen of the peripheral lungs and collect samples via precise positioning for lavage or puncture biopsy [16]. At this stage, this technique has been widely used in clinical practice, particularly for diagnosing early-stage lung cancer [17, 18]. However, its application in the field of TB is still relatively rare. Owing to the limited sampling via EBUS-GS, diagnosis based on histopathological biopsy alone is challenging, and diagnostic errors can easily occur. Therefore, the current study aimed to evaluate the use of molecular biology-based diagnostic techniques (e.g., Xpert MTB/RIF assay) to facilitate a comprehensive clinical diagnosis of TB. Furthermore, the diagnostic efficacy of the Xpert MTB/RIF assay combined with EBUS-GS for peripheral nodular PTB was examined.

Methods

Study design

This single-center retrospective study was conducted at the Tuberculosis Diagnosis and Treatment Center of Zhejiang Chinese and Western Medicine Integrated Hospital from June 2020 to October 2023. The digital medical records of patients suspected of having peripheral nodular PTB who were admitted to our facility were examined. All patients who underwent comprehensive laboratory tests, including routine blood test, coagulation function test, blood biochemical indicator test, tumor marker examination, and T-SPOT.TB assay, were enrolled. After screening for bronchoscopy contraindications, patients underwent lung puncture biopsy using EBUS-GS. Next, they immediately underwent bronchial flushing. EBUS-GS biopsy samples were sent for pathological examination, and bronchial flushing fluid samples were sent for acid-fast bacilli (AFB) smear, culture, and Xpert MTB/RIF assay.

PTB was diagnosed by clinicians based on the diagnostic standard of the People’s Republic of China for Tuberculosis (WS 288–2017). The final clinical diagnostic standard was a composite reference standard (CRS). For PTB diagnosis, patients must meet at least one of the following criteria: (1) positive results in bronchial flushing fluid microbiological tests (including culture or Xpert MTB/RIF assay); (2) histopathological findings on lung puncture consistent with TB pathology, with typical lesions of caseous necrotic granuloma and Langerhans’ giant cells observed around the lesion; and (3) reduction or disappearance of lung nodules after 1 month of anti-TB treatment. Otherwise, patients were diagnosed with non-PTB conditions.

The inclusion criteria were as follows: (1) patients with solid or subsolid solitary lung nodules with a diameter of 8–30 mm on chest CT, located in the outer area of the lung; (2) those without significant abnormalities of the heart or lung, blood clotting disorders, or any other contraindications for standard bronchoscopy; and (3) those not taking oral anticoagulant medications. The exclusion criteria were as follows: (1) patients with different lung lesions located in the inner and middle bands of the lungs; (2) patients with multiple areas of patchy, solid, or cavitated lesions on lung CT; (3) those with lesions located in a subsegment of the bronchus that could be accessed via plain bronchoscopy; and (4) those with an unclear final diagnosis. Due to the retrospective nature of the study, the need to obtain informed consent was waived. This research was evaluated and approved by the Ethics Committee of Zhejiang Chinese and Western Medicine Integrated Hospital (2023–09–025). Moreover, it was performed in accordance with the principles of the Declaration of Helsinki.

Experimental methods

Equipment and instruments

A bronchoscope (Olympus, BF-P260F) with an external diameter of 4.0 mm and an internal diameter of 2.0 mm, ultrasound imaging equipment (Olympus, EndoEchoEU-M2000), ultrasound probe driver (Olympus; MAJ-1720), ultrasound probe (Olympus; UM-S20-17 S) with an external diameter of 1.4 mm, GS (Olympus, K-201) with an external diameter of 1.95 mm, and disposable biopsy forceps were used.

Procedure

Before EBUS-GS examination, all patients underwent thin-layer chest CT (0.75-mm slice thickness; AS 64-slice CT system, PHILIPS, Netherlands). Chest CT images were reviewed by two experienced pulmonologists before the procedure, who then used the bronchial pathway to target the lesion. Before surgery, the anesthesiologist performed transoral laryngeal mask mechanical ventilation under intravenous anesthesia after 6 h of food and water fasting. After the administration of anesthesia, the scope was introduced into healthy and affected bronchi, and their branches were routinely explored sequentially. Then, according to the virtual path established on CT, the operator entered the subsegmental bronchus where the lesion was located, and the ultrasound probe was used to reach the bronchial lumen of the target lesion via the biopsy hole. After their detection, the abnormal echoes were localized. After fixing the bronchoscope at the same location, the ultrasound probe was removed and the biopsy forceps were fed into the biopsy tube via the GS to obtain biopsy samples from a region close to the lesion site. The biopsy forceps were withdrawn after repeated clamping of 3–5 pieces of tissue. Then, the punctured tissues were sent for routine pathological examination. Subsequently, approximately 60 mL of saline was injected into the bronchial lumen of the lesion via the GS for flushing. The bronchial flushing fluid was absorbed back into a sterile container, uniformly aliquoted, and subjected to AFB smear, culture, and Xpert MTB/RIF assay.

Diagnostic specimen handling

AFB smear

About 1 mL of centrifuged lavage fluid samples was placed on a dry and clean glass slide, left to dry, and subsequently heat fixed and stained using Ziehl–Neelsen stain. After placing the stained sample under a microscope, at least one antacid bacillus was observed in 300 different fields of view. Thus, the result was considered positive.

Culture

An equivalent amount of 4% sodium hydroxide solution was combined with the lavage sample, and the mixture was left to stand for 15 min. Subsequently, sterile phosphate buffer was added until the total volume reached 50 mL. After centrifugation, the precipitate was inoculated into the liquid medium. For liquid culture, the BACTEC MGIT 960 Mycobacterium culture system (BD Diagnostic Systems, Sparks, MD) was used.

Xpert MTB/RIF assay

Fresh bronchoalveolar lavage fluid (BALF) samples were centrifuged, yielding a 1-mL sediment. This sediment was then combined with 2 mL of the sample treatment solution. The mixture was left at room temperature for 15 min and then vigorously vortexed for 8 min. Next, 2 mL of the mixture was added to the Xpert MTB/RIF cartridge (Cepheid, USA), which was then loaded onto the testing module. Finally, the system automatically reported results within 2 h.

Pathological examination

A neutral formalin fixative was used to fully soak the specimen, after which pathological specimens were obtained. Next, a series of processes such as dehydration, embedding, sectioning, staining, and filming of the sampled tissues were performed. The pathological sections were then analyzed under a microscope. Results showed the presence of caseous necrosis in the lesion. Hence, a pathological diagnosis of the disease was made based on the patient’s clinical information and pathological and morphological characteristics.

Statistical analysis

SPSS software version 22.0 (SPSS Inc., Chicago, USA) was used for statistical analysis. MedCalc Statistical v15.2.2 software (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org) was used to calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the receiver operating characteristic curve (AUC), and 95% confidence interval (CI) of the four tests. CRS was selected as the final diagnostic standard to assess the diagnostic accuracy of the tests. Additionally, paired data were compared using the McNemar’s test. AUCs were compared using the Z-test. To compare internal variations among the four tests, a Venn diagram (https://www.xiantaozi.com/literatures) was constructed. A P-value of < 0.05 was considered to indicate statistical significance.

Results

Baseline clinical characteristics of the participants

The medical records of the patients (n = 260) clinically suspected of having peripheral nodular PTB and admitted to our institution between June 2020 and October 2023 were examined. However, 28 patients with insufficient data were excluded from the study. Finally, 232 patients were included in this retrospective analysis. The average age of the patients was 51.41 ± 16.99 years, and 151 (65.09%) of them were male. In total, 175 (75.43%) patients showed positive results in the T-SPOT.TB assay, and 79 (34.05%) were previously diagnosed with PTB and were receiving anti-TB treatment. Meanwhile, all patients tested negative for the human immunodeficiency virus. Based on CRS, which is the ultimate diagnostic criteria, 146 (62.93%) patients were diagnosed with peripheral nodular PTB and 86 (37.07%) had no PTB. In the non-PTB group, 13 patients were diagnosed with lung cancer, 14 with organizing pneumonia, 45 with bacterial pneumonia, 7 with nontuberculous mycobacterial pulmonary disease, 4 with fungal pneumonia, 2 with cryptococcal pneumonia, and 1 with mycoplasma pneumonia. Figure 1 shows the status of 260 patients who were admitted due to suspicion of peripheral nodular PTB.

Fig. 1 Status of 260 patients with suspected peripheral nodular PTB

Diagnostic performance of AFB smear, culture, Xpert MTB/RIF assay, and pathological examination for peripheral nodular PTB

The overall sensitivity, specificity, PPV, NPV, and AUC of AFB smear using EBUS-GS for detecting peripheral nodular PTB were 8.22% (95% CI: 4.32–13.92%), 97.67% (91.85–99.72%), 85.71% (57.19–98.22%), 38.53% (32.04–45.34%), and 0.53 (0.46–0.60), respectively.

The overall sensitivity, specificity, PPV, NPV, and AUC of culture using EBUS-GS for detecting peripheral nodular PTB were 31.51% (95% CI: 24.08–39.71%), 100.00% (95.80–100.00%), 100.00% (92.29–100.00%), 46.24% (38.91–53.68%), and 0.66 (0.59–0.72), respectively.

The overall sensitivity, specificity, PPV, NPV, and AUC of the Xpert MTB/RIF assay using EBUS-GS for detecting peripheral nodular PTB were 47.26% (95% CI: 38.95–55.68%), 100.00% (95.80–100.00%), 100.00% (94.79–100.00%), 52.76% (44.80–60.62%), and 0.74 (0.67–0.79), respectively.

The overall sensitivity, specificity, PPV, NPV, and AUC of pathological examination using EBUS-GS for detecting peripheral nodular PTB were 23.97% (95% CI: 17.30–31.73%), 97.67% (91.85–99.72%), 94.59% (81.81–99.34%), 43.08% (36.02–50.34%), and 0.61 (0.54–0.67), respectively.

The results of the four tests are displayed in Table 1.

Table 1 The diagnostic accuracy of the four tests for peripheral nodular pulmonary tuberculosis

Test	Sensitivity
(95% CI)	Specificity
(95% CI)	PPV
(95% CI)	NPV
(95% CI)	AUC
(95% CI)	
AFB smear	8.22

(4.32–13.92)

	97.67

(91.85–99.72)

	85.71

(57.19–98.22)

	38.53

(32.04–45.34)

	0.53

(0.46–0.60)

	
Culture	31.51

(24.08–39.71)

	100.00

(95.80–100.00)

	100.00

(92.29–100.00)

	46.24

(38.91–53.68)

	0.66

(0.59–0.72)

	
Xpert MTB/RIF	47.26

(38.95–55.68)

	100.00

(95.80–100.00)

	100.00

(94.79–100.00)

	52.76

(44.80–60.62)

	0.74

(0.69–0.79)

	
Pathological examination	23.97

(17.30–31.73)

	97.67

(91.85–99.72)

	94.59

(81.81–99.34)

	43.08

(36.02–50.34)

	0.61

(0.54–0.67)

	

Comparison of the diagnostic accuracies of the four tests during EBUS-GS

The diagnostic accuracies of AFB smear, culture, Xpert MTB/RIF assay, and pathological examination combined with EBUS-GS were compared in patients suspected of having peripheral nodular PTB, with CRS being used as the ultimate diagnostic criterion. AFB smear had the lowest diagnostic accuracy among the four diagnostic methods, and the difference between each of the two tests was statistically significant (P < 0.01). Both culture and pathological examination had moderate diagnostic accuracy without a statistically significant difference (P > 0.05). Moreover, the Xpert MTB/RIF assay showed the greatest diagnostic accuracy (P < 0.01). Table 2 shows the comparison of the tests. Figure 2 depicts the receiver operating characteristic curves of the four tests.

Table 2 The diagnostic accuracy of MTB culture, Xpert MTB/RIF assay, and pathological examination for peripheral nodular PTB

Test	Sensitivity
(P-value)	Specificity
(P-value)	AUC
(P-value)	
Culture vs.

Xpert MTB/RIF

	< 0.001	1.000	< 0.001	
Culture vs.

pathological examination

	0.843	< 0.001	0.068	
Xpert MTB/RIF vs.

pathological examination

	< 0.001	< 0.001	< 0.001	
AUC: area under the curve

Fig. 2 shows the ROC curves of the four tests

Complications

Among the 232 patients who underwent EBUS-GS, 7 (3.02%) presented with pneumothorax. Furthermore, five patients recovered with oxygen therapy, and two required thoracic drainage. In total, two (0.87%) patients had intra-airway hemorrhage, which was treated with topical epinephrine spray.

Discussion

The diagnosis of isolated nodular lesions that are suspected as PTB is challenging [19], particularly if the nodular foci are located in the peripheral bands of the lung, which are not easily accessible via conventional bronchoscopy. This leads to a decreased detection rate, making it difficult to obtain a definitive diagnosis. It is difficult to distinguish PTB from primary lung cancer in the peripheral lungs. Even in regions where TB is endemic, it is still misdiagnosed as primary lung cancer [20, 21]. Therefore, the EBUS-GS technique should be adopted, which is a more accurate, minimally invasive, and safer method of obtaining specimens when combined with TB molecular biology testing, thereby improving the diagnostic yield of peripheral nodular PTB [22].

Results showed that AFB smear with EBUS-GS had the least diagnostic accuracy for peripheral nodular PTB (with a sensitivity of 8.22%, specificity of 97.67%, and AUC of 0.53). These values were similar to those reported by Yao et al. [23]. In our previous study, the detection efficacy of AFB smear was higher than that in the present study, probably due to the fact that the patients in the previous study had a wider range of lung lesions, which made it easier to obtain positive results [24]. However, AFB smear is not a reliable method for MTB detection, and a positive outcome does not conclusively confirm PTB. In our study, two patients with positive AFB smear were diagnosed with nontuberculous mycobacterial infection, and the bacterial strains were identified via culture. Thus, AFB smear, which is the conventional diagnostic approach for TB, has the least diagnostic precision.

Culture, which is another traditional diagnostic technique, showed a fairly high level of accuracy. The current study revealed that the sensitivity, specificity, and AUC of culture were 31.51%, 100.00%, and 0.66, respectively. These results were significantly better than those of AFB smear (P < 0.001). However, culture has a disadvantage that cannot be ignored, i.e., the need for several weeks to obtain the results. Thus, it cannot be used as an early diagnostic technique [25]. The delayed intermediate time affects the identification and management of PTB, which may lead to incorrect diagnosis and transmission [26].

Using EBUS-GS, we successfully acquired biopsy samples from solitary nodular TB. The sensitivity, specificity, and AUC of pathological examination were 23.97%, 97.67%, and 0.61, respectively. Its diagnostic efficacy was similar to that of culture (P > 0.05), and both tests had significantly higher diagnostic efficacy than AFB smear (P < 0.001). However, pathological examination also requires few days to obtain results. The diagnostic sensitivity of pathological examination during EBUS-GS was significantly lower than that of CT-guided lung puncture biopsy, owing to the narrow inner diameter of the GS and limited extent of operation using the biopsy needle [27]. Inserting the needle vertically to obtain tissue samples from deep within the lesion is challenging, leading to reduced sensitivity of pathological examination. Occasionally, TB is pathologically challenging to distinguish from nontuberculous mycobacterial lung disease [28]. In this study, for a patient with a pathological diagnosis of granulomatous inflammation who showed a positive culture for nontuberculous mycobacteria, the final diagnosis was nontuberculous mycobacterial lung disease. Furthermore, in one case, the pathological examination results were indicative of chronic suppurative inflammation with suspected granuloma formation, which was eventually diagnosed as bacterial pneumonia after 2 weeks of anti-infective treatment with cefoperazone sodium and sulbactam sodium. In the non-PTB group, 13 patients were newly diagnosed with lung cancer, which facilitated early surgical treatment and improved the prognosis.

The current study showed that the Xpert MTB/RIF assay in conjunction with EBUS-GS had the highest efficacy in diagnosing peripheral nodular PTB. Additionally, the results were obtained within 2 h, and the method confirmed rifampicin resistance, thereby enhancing its clinical utility. However, the sensitivity was 47.26%, lower than that reported in a previous study, which revealed that the sensitivity of the Xpert MTB/RIF assay using BALF samples was 58.9% in patients with smear-negative or sputum-sparse PTB [29]. This could be attributed to the fact that our study involved lesion sizes of 8–30 mm, which were significantly smaller than the lesions in other studies. Moreover, the lesion sites in our study were located in the peripheral lung bands away from the central bronchiole, and conventional bronchoscopy cannot easily reach the lesions. Cao et al. found that when using EBUS-GS for the same lesion type, the sensitivity of the Xpert MTB/RIF assay was 34.78%, with an AUC of 0.674, which was slightly lower than that in our study. However, when using puncture tissue for Xpert MTB/RIF assay, the sensitivity and AUC were significantly higher, but with more complications [30]. In general, EBUS-GS causes less harm and is associated with fewer issues than conventional invasive examinations [31]. Meanwhile, the Xpert MTB/RIF assay can provide a high and relatively rapid diagnostic output [32]. The use of both techniques yields exceptional diagnostic outcomes for isolated pulmonary nodules caused by MTB and is beneficial in distinguishing nontuberculous respiratory diseases. In our study, we found that the Xpert MTB/RIF assay could diagnose 18 more patients with PTB, whereas the other tests yielded negative results. Controlling TB transmission is facilitated by a considerably increased rate of detection, which provides timely access to anti-TB treatment and decreases the spread of bacteria.

This study had some limitations. It was conducted retrospectively at a single center and had a limited number of participants. Therefore, the diagnostic significance of the Xpert MTB/RIF assay combined with EBUS-GS for solitary pulmonary nodules caused by MTB requires validation through a clinical multicenter study. Additionally, the operators of EBUS-GS need to have a high level of operating skills. Some lesions may not be accessible, or there could be failure in puncturing due to the angle of the bronchoscope.

Conclusion

The combination of Xpert MTB/RIF and EBUS-GS is clinically valuable in the diagnosis of peripheral isolated PTB, as it has good sensitivity and high specificity. Therefore, implementation of this technique in hospitals in TB endemic areas can help in the early screening of PTB and control of TB epidemics.

Acknowledgements

We would like to express our feelings to the patients and colleagues in our department.

Author contributions

L.Z. and Q.H. designed the study protocol and reviewed the literature. Y.Y. and X.R. collected the clinical data. Q.H. and H.L. performed the statistical analysis of the data. L.Z. and Y.Y. completed the writing of the first draft. Q.H. reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding

Funding for this research was provided by the HangZhou Municipal Health Commission (Grant number: A20200673) and the Health Commission of Zhejiang Province (Grant number: 2022KY984).

Data availability

Data is provided within the manuscript, and is available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Due to the retrospective nature of the study, the need to obtain informed consent was waived. This research was evaluated and approved by the Ethics Committee of Zhejiang Chinese and Western Medicine Integrated Hospital (2023–09–025). Moreover, it was performed in accordance with the principles of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

AFB smear Acid-fast bacilli smear

AUC Area under the curve

BALF Bronchoalveolar lavage fluid

CI Confidence interval

CRS Composite reference standard

CT Computed tomography

EBUS-GS Endobronchial ultrasonography with a guide sheath

EBUS Endobronchial ultrasonography

EPTB Extrapulmonary tuberculosis

GS Guide sheath

MTB Mycobacterium tuberculosis

NPV Negative predictive value

PPV Positive predictive value

PTB Pulmonary tuberculosis

TB Tuberculosis

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Pathakumari B Devasundaram S Raja A Altered expression of antigen-specific memory and regulatory T-cell subsets differentiate latent and active tuberculosis Immunology 2018 153 325 36 10.1111/imm.12833 28881482
Pathakumari B, Devasundaram S, Raja A. Altered expression of antigen-specific memory and regulatory T-cell subsets differentiate latent and active tuberculosis. Immunology. 2018;153:325–36.28881482
2. Bagcchi S WHO’s Global Tuberculosis Report 2022 Lancet Microbe 2023 4 e20 10.1016/S2666-5247(22)00359-7 36521512
Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe. 2023;4:e20.36521512
3. Antonangelo L Faria CS Sales RK Tuberculous pleural effusion: diagnosis & management Expert Rev Respir Med 2019 13 747 59 10.1080/17476348.2019.1637737 31246102
Antonangelo L, Faria CS, Sales RK. Tuberculous pleural effusion: diagnosis & management. Expert Rev Respir Med. 2019;13:747–59.31246102
4. Toujani S Ben Salah N Cherif J Mjid M Ouahchy Y Zakhama H [Primary infection and pulmonary tuberculosis] Rev Pneumol Clin 2015 71 73 82 10.1016/j.pneumo.2015.02.001 25749628
Toujani S, Ben Salah N, Cherif J, Mjid M, Ouahchy Y, Zakhama H, et al. Primary infection and pulmonary tuberculosis. Rev Pneumol Clin. 2015;71:73–82.25749628
5. Suárez I Fünger SM Kröger S Rademacher J Fätkenheuer G Rybniker J The diagnosis and treatment of tuberculosis Dtsch Arztebl Int 2019 116 729 35 31755407
Suárez I, Fünger SM, Kröger S, Rademacher J, Fätkenheuer G, Rybniker J. The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int. 2019;116:729–35.31755407
6. Liu HC Gao YL Li DF Zhao XY Pan YQ Zhu CT Value of Xpert MTB/RIF using bronchoalveolar lavage fluid for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis J Clin Microbiol 2021 59 e02170 20 10.1128/JCM.02170-20 33177121
Liu HC, Gao YL, Li DF, Zhao XY, Pan YQ, Zhu CT. Value of Xpert MTB/RIF using bronchoalveolar lavage fluid for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. J Clin Microbiol. 2021;59:e02170–20.33177121
7. Liu X Chen Y Ouyang H Liu J Luo X Huang Y Tuberculosis diagnosis by metagenomic next-generation sequencing on bronchoalveolar lavage fluid: a cross-sectional analysis Int J Infect Dis 2021 104 50 7 10.1016/j.ijid.2020.12.063 33359946
Liu X, Chen Y, Ouyang H, Liu J, Luo X, Huang Y, et al. Tuberculosis diagnosis by metagenomic next-generation sequencing on bronchoalveolar lavage fluid: a cross-sectional analysis. Int J Infect Dis. 2021;104:50–7.33359946
8. Lam S Shah PL Bronchoscopic diagnosis of peripheral lung lesions Respiration 2021 100 764 6 10.1159/000516393 34004606
Lam S, Shah PL. Bronchoscopic diagnosis of peripheral lung lesions. Respiration. 2021;100:764–6.34004606
9. Livi V Barisione E Zuccatosta L Romagnoli M Praticò A Michieletto L Competence in navigation and guided transbronchial biopsy for peripheral pulmonary lesions Panminerva Med 2019 61 280 9 10.23736/S0031-0808.18.03568-1 30394715
Livi V, Barisione E, Zuccatosta L, Romagnoli M, Praticò A, Michieletto L, et al. Competence in navigation and guided transbronchial biopsy for peripheral pulmonary lesions. Panminerva Med. 2019;61:280–9.30394715
10. Biswas A Mehta HJ Sriram PS Diagnostic yield of the virtual bronchoscopic navigation system guided sampling of peripheral lung lesions using ultrathin bronchoscope and protected bronchial brush Turk Thorac J 2019 20 6 11 10.5152/TurkThoracJ.2018.18030 30664420
Biswas A, Mehta HJ, Sriram PS. Diagnostic yield of the virtual bronchoscopic navigation system guided sampling of peripheral lung lesions using ultrathin bronchoscope and protected bronchial brush. Turk Thorac J. 2019;20:6–11.30664420
11. Harris K Puchalski J Sterman D Recent advances in bronchoscopic treatment of peripheral lung cancers Chest 2017 151 674 85 10.1016/j.chest.2016.05.025 27292045
Harris K, Puchalski J, Sterman D. Recent advances in bronchoscopic treatment of peripheral lung cancers. Chest. 2017;151:674–85.27292045
12. Kurihara Y Tashiro H Takahashi K Tajiri R Kuwahara Y Kajiwara K Factors related to the diagnosis of lung cancer by transbronchial biopsy with endobronchial ultrasonography and a guide sheath Thorac Cancer 2022 13 3459 66 10.1111/1759-7714.14705 36263938
Kurihara Y, Tashiro H, Takahashi K, Tajiri R, Kuwahara Y, Kajiwara K, et al. Factors related to the diagnosis of lung cancer by transbronchial biopsy with endobronchial ultrasonography and a guide sheath. Thorac Cancer. 2022;13:3459–66.36263938
13. Martini K Loubet A Bankier A Bouam S Morand P Cassagnes L Nodular reverse halo sign in active pulmonary tuberculosis: a rare CT feature? Diagn Interv Imaging 2020 101 281 7 10.1016/j.diii.2020.01.013 32057699
Martini K, Loubet A, Bankier A, Bouam S, Morand P, Cassagnes L, et al. Nodular reverse halo sign in active pulmonary tuberculosis: a rare CT feature? Diagn Interv Imaging. 2020;101:281–7.32057699
14. Moreira-Neto C Moreira C Jr Tolentino D Duker JS Nodular posterior scleritis associated with presumed ocular tuberculosis: a multimodal imaging case report Am J Ophthalmol Case Rep 2019 16 100558 10.1016/j.ajoc.2019.100558 31650086
Moreira-Neto C, Moreira C Jr., Tolentino D, Duker JS. Nodular posterior scleritis associated with presumed ocular tuberculosis: a multimodal imaging case report. Am J Ophthalmol Case Rep. 2019;16:100558.31650086
15. Kim J Lee KH Cho JY Kim J Shin YJ Lee KW Usefulness of CT-guided percutaneous transthoracic needle lung biopsies in patients with suspected pulmonary infection Korean J Radiol 2020 21 526 36 10.3348/kjr.2019.0492 32323498
Kim J, Lee KH, Cho JY, Kim J, Shin YJ, Lee KW. Usefulness of CT-guided percutaneous transthoracic needle lung biopsies in patients with suspected pulmonary infection. Korean J Radiol. 2020;21:526–36.32323498
16. Zhang QC Xuan WX Li HL Sun GN Cheng DJ Wang Z Diagnostic value of LungPoint navigation combined with EBUS-GS & ROSE in peripheral pulmonary nodules Indian J Med Res 2022 156 529 34 10.4103/ijmr.IJMR_2114_19 36751749
Zhang QC, Xuan WX, Li HL, Sun GN, Cheng DJ, Wang Z, et al. Diagnostic value of LungPoint navigation combined with EBUS-GS & ROSE in peripheral pulmonary nodules. Indian J Med Res. 2022;156:529–34.36751749
17. Zhu J Tang F Gu Y A prospective study on the diagnosis of peripheral lung cancer using endobronchial ultrasonography with a guide sheath and computed tomography-guided transthoracic needle aspiration Ther Adv Med Oncol 2018 10 1758834017752269 10.1177/1758834017752269 29383040
Zhu J, Tang F, Gu Y. A prospective study on the diagnosis of peripheral lung cancer using endobronchial ultrasonography with a guide sheath and computed tomography-guided transthoracic needle aspiration. Ther Adv Med Oncol. 2018;10:1758834017752269.29383040
18. Tanaka A Akamatsu H Kawabata H Ariyasu H Nakamura Y Yamamoto N Peripheral pulmonary carcinoid tumor diagnosed by endobronchial-ultrasound-guided bronchoscopy Respirol Case Rep 2016 4 10 2 10.1002/rcr2.139 26839693
Tanaka A, Akamatsu H, Kawabata H, Ariyasu H, Nakamura Y, Yamamoto N. Peripheral pulmonary carcinoid tumor diagnosed by endobronchial-ultrasound-guided bronchoscopy. Respirol Case Rep. 2016;4:10–2.26839693
19. Kim CH Lim JK Lee SY Won DI Cha SI Park JY Predictive factors for tuberculosis in patients with a TB-PCR-negative bronchial aspirate Infection 2013 41 187 94 10.1007/s15010-012-0394-7 23283746
Kim CH, Lim JK, Lee SY, Won DI, Cha SI, Park JY, et al. Predictive factors for tuberculosis in patients with a TB-PCR-negative bronchial aspirate. Infection. 2013;41:187–94.23283746
20. Sun W Zhang L Liang J Li X Yang Y Sun W Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: a systematic review and meta-analysis Epidemiol Infect 2022 150 e43 10.1017/S0950268822000176 35105410
Sun W, Zhang L, Liang J, Li X, Yang Y, Sun W, et al. Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2022;150:e43.35105410
21. Wang XL Shan W Application of dynamic CT to identify lung cancer, pulmonary tuberculosis, and pulmonary inflammatory pseudotumor Eur Rev Med Pharmacol Sci 2017 21 4804 9 29164583
Wang XL, Shan W. Application of dynamic CT to identify lung cancer, pulmonary tuberculosis, and pulmonary inflammatory pseudotumor. Eur Rev Med Pharmacol Sci. 2017;21:4804–9.29164583
22. Zhu J Gu Y Diagnosis of peripheral pulmonary lesions using endobronchial ultrasonography with a guide sheath and computed tomography guided transthoracic needle aspiration Clin Respir J 2019 13 765 72 10.1111/crj.13088 31487103
Zhu J, Gu Y. Diagnosis of peripheral pulmonary lesions using endobronchial ultrasonography with a guide sheath and computed tomography guided transthoracic needle aspiration. Clin Respir J. 2019;13:765–72.31487103
23. Yao L Chen S Sha W Gu Y The diagnostic performance of endobronchial ultrasound with Xpert MTB/RIF Ultra in smear-negative pulmonary tuberculosis BMC Infect Dis 2023 23 107 10.1186/s12879-023-08073-7 36814228
Yao L, Chen S, Sha W, Gu Y. The diagnostic performance of endobronchial ultrasound with Xpert MTB/RIF ultra in smear-negative pulmonary tuberculosis. BMC Infect Dis. 2023;23:107.36814228
24. Zhou L Zou X Hu Q Hua H Qi Q Determination of the diagnostic accuracy of nanopore sequencing using bronchoalveolar lavage fluid samples from patients with sputum-scarce pulmonary tuberculosis J Infect Chemother 2023 30 98 103 10.1016/j.jiac.2023.09.014 37714266
Zhou L, Zou X, Hu Q, Hua H, Qi Q. Determination of the diagnostic accuracy of nanopore sequencing using bronchoalveolar lavage fluid samples from patients with sputum-scarce pulmonary tuberculosis. J Infect Chemother. 2023;30:98–103.37714266
25. Noussair L Bert F Leflon-Guibout V Métivier R Chauvet C Napol C Evaluation of the culture-enhanced Xpert MTB/RIF assay for the diagnosis of smear-negative tuberculosis Med Mal Infect 2019 49 467 70 10.1016/j.medmal.2018.11.004 30528069
Noussair L, Bert F, Leflon-Guibout V, Métivier R, Chauvet C, Napol C, et al. Evaluation of the culture-enhanced Xpert MTB/RIF assay for the diagnosis of smear-negative tuberculosis. Med Mal Infect. 2019;49:467–70.30528069
26. Said B Charlie L Getachew E Wanjiru CL Abebe M Manyazewal T Molecular bacterial load assay versus culture for monitoring treatment response in adults with tuberculosis SAGE Open Med 2021 9 20503121211033470 10.1177/20503121211033470 34349999
Said B, Charlie L, Getachew E, Wanjiru CL, Abebe M, Manyazewal T. Molecular bacterial load assay versus culture for monitoring treatment response in adults with tuberculosis. SAGE Open Med. 2021;9:20503121211033470.34349999
27. Brioulet J David A Sagan C Cellerin L Frampas E Morla O Percutaneous CT-guided lung biopsy for the diagnosis of persistent pulmonary consolidation Diagn Interv Imaging 2020 101 727 32 10.1016/j.diii.2020.07.007 32811758
Brioulet J, David A, Sagan C, Cellerin L, Frampas E, Morla O. Percutaneous CT-guided lung biopsy for the diagnosis of persistent pulmonary consolidation. Diagn Interv Imaging. 2020;101:727–32.32811758
28. Jain D Ghosh S Teixeira L Mukhopadhyay S Pathology of pulmonary tuberculosis and non-tuberculous mycobacterial lung disease: facts, misconceptions, and practical tips for pathologists Semin Diagn Pathol 2017 34 518 29 10.1053/j.semdp.2017.06.003 28693908
Jain D, Ghosh S, Teixeira L, Mukhopadhyay S. Pathology of pulmonary tuberculosis and non-tuberculous mycobacterial lung disease: facts, misconceptions, and practical tips for pathologists. Semin Diagn Pathol. 2017;34:518–29.28693908
29. Yang J Shen Y Wang L Ju L Wu X Wang P Efficacy of the Xpert Mycobacterium tuberculosis/rifampicin assay for diagnosing sputum-smear negative or sputum-scarce pulmonary tuberculosis in bronchoalveolar lavage fluid Int J Infect Dis 2021 107 121 6 10.1016/j.ijid.2021.04.040 33864923
Yang J, Shen Y, Wang L, Ju L, Wu X, Wang P, et al. Efficacy of the Xpert Mycobacterium tuberculosis/rifampicin assay for diagnosing sputum-smear negative or sputum-scarce pulmonary tuberculosis in bronchoalveolar lavage fluid. Int J Infect Dis. 2021;107:121–6.33864923
30. Cao J Gu Y Wu XC Cheng LP Wang L Qu QR EBUS-GS with the GeneXpert MTB/RIF assay for diagnosis of Mycobacterium tuberculosis infection of isolated pulmonary nodules Eur J Med Res 2023 28 370 10.1186/s40001-023-01331-z 37742037
Cao J, Gu Y, Wu XC, Cheng LP, Wang L, Qu QR, et al. EBUS-GS with the GeneXpert MTB/RIF assay for diagnosis of Mycobacterium tuberculosis infection of isolated pulmonary nodules. Eur J Med Res. 2023;28:370.37742037
31. Xu CH Yuan Q Yu LK Wang W Lin Y Endobronchial ultrasound transbronchial biopsy with guide-sheath for the diagnosis of solitary pulmonary nodules Oncotarget 2017 8 58272 7 10.18632/oncotarget.16813 28938554
Xu CH, Yuan Q, Yu LK, Wang W, Lin Y. Endobronchial ultrasound transbronchial biopsy with guide-sheath for the diagnosis of solitary pulmonary nodules. Oncotarget. 2017;8:58272–7.28938554
32. Chhajed PN Vaidya PJ Mandovra NP Chavhan VB Lele TT Nair R EBUS-TBNA in the rapid microbiological diagnosis of drug-resistant mediastinal tuberculous lymphadenopathy ERJ Open Res 2019 5 00008 2019 10.1183/23120541.00008-2019 31754620
Chhajed PN, Vaidya PJ, Mandovra NP, Chavhan VB, Lele TT, Nair R, et al. EBUS-TBNA in the rapid microbiological diagnosis of drug-resistant mediastinal tuberculous lymphadenopathy. ERJ Open Res. 2019;5:00008–2019.31754620
